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EDITORIAL
Welcome to Edition 52 of Blood and Transplant Matters 
and I hope you enjoyed the last edition and found areas of 
interest and use.
Firstly, may a big thank you be sent to John Forsythe, 
who is leaving the Editorial Board, for his great contribution 
to Blood and Transplant Matters. Secondly a warm welcome 
to Dale Gardiner, who joins the Editorial Board, but will, still, 
also, continue with his interesting and informative articles.
This edition commences with a solution to the problem 
of where and how to obtain services. In this case, where 
and how to obtain Therapeutic Apheresis Service in 
the South West. Following the success of a Web-Based 
Roadmap detailing the Apheresis Service provided for 
each Trust in the North West of England and North Wales. 
Hollie McKenna describes the process undertaken for the 
South West region of England. This is followed by another 
electronic mobile solution, in this case where to easily and 
quickly find evidence based guidance to aid appropriate 
transfusion of blood components. Denise Watson, 
Amanpreet Dhesi, Paul Watson, Helen New and Janet 
Birchall outline the development of a Blood Component 
App for smart phones, which will help front line staff make 
the correct transfusion decisions.
The next few articles take a varied look at organ 
donation, starting with Oluwayemisi Alabi, Zoe Butler, Laura 
Machin, Sarah Ralley and Mark Wilkinson taking a look at 
communication barriers and how to raise the profile of organ 
donation amongst a local student population by creating 
Student Representative Posts. These posts had an initial aim 
of encouraging the local community to inform their families 
of their wish to be potential organ donors. How this was 
achieved is fully described. Next, Michael Nicholson gives 
a brief overview of structure of the National Institute for 
Health Research (NIHR) Blood and Transplant research Unit 
in Organ Donation of transplantation, along with a brief 
outline of the various research themes and cross-cutting 
themes. Finally in this section Dale Gardiner provides the 
case for donation memorials and provides a few examples.
Changing tack slightly, Laura Unitt describes the progress 
NHS Blood and Transplant (NHSBT) has had with the 
Apprenticeship Scheme so far, with over 120 started or 
registered interest to start an apprenticeship programme. 
Chris Sims follows with the reasons for considering a new 
blood centre to replace Leeds and Sheffield Blood Centres 
and gives a taste of how the future will look.
As always, there are both CPD Questions based upon 
these articles, with answers. Some interesting clinical 
situations with suggested approaches and some references, 
which I hope are both interesting and informative.
Have a happy read. All good points are due to the authors, 
any mistakes are mine. Any comments should be sent to 
myself or my hard working Editorial Assistant Lynne Hodkin 
at blood&transplantmatters@nhsbt.nhs.uk.
The results of our reader survey are now available and 
show that Blood and Transplant Matters is equally read by 
NHSBT and non-NHSBT staff, providing a good spread of 
current information with the CPD Questions (and answers) 
and clinical cases provide particularly popular.
Looking to the future we may be producing forthcoming 
editions as an online version only – no distribution of print 
editions – which will enable further developments. I would 
be grateful for comments to be sent either directly to myself 
or to Lynne Hodkin via our email address given above.
 
Rob Webster 
Consultant Haematologist, (Editor) 
NHSBT, Sheffield 
Email: robert.webster@nhsbt.nhs.uk
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Development of a Web-Based Roadmap to Improve Access to Apheresis 
Services for Patients in the South West of England
Background
NHS Blood and Transplant (NHSBT) are major providers 
of Therapeutic Apheresis Services (TAS) to the NHS, 
treatments provided include: Automated Red Cell Exchange, 
Plasma Exchange (PEX), Extracorporeal Photopheresis, 
Stem Cell Collection, Low Density Lipoprotein Removal and 
Leucodepletion. The specialist TAS nursing and medical 
teams provide routine and 24/7 emergency services 
from eight units across England. NHSBT are not the only 
provider of TAS services, some Hospitals also deliver a 
comprehensive and seven day apheresis service through 
robust in-house arrangements utilising Trust resources. For 
other Hospitals, access to services is fractured or unclear, 
particularly as the apheresis service provider often varies 
between clinical specialties.
The British Committee for Standards in Haematology 
have emphasised that time-to-treatment is a critical 
factor in determining patient outcomes in guidelines 
for the diagnosis and management of Thrombotic 
Thrombocytopenic Purpura (TTP) and other thrombotic 
microangiopathies (Scully et al, 2012); it is therefore 
necessary that the referral process is clear, to enable 
efficient treatment delivery. Furthermore, there is a 
requirement to identify service gaps which could account 
for delays in apheresis treatment delivery.
A web-based roadmap, detailing the apheresis service 
providers for each Trust in the North West (NW) of England 
and North Wales (Alimam et al, 2015), was created in 
2013. No service delivery failures have since been reported 
in the region. An annual NHSBT User Satisfaction Survey, 
sent to Consultants who have referred patients to TAS in 
the previous year, highlighted scope to improve the clarity 
of the referral process and accessibility to referral forms. 
NHSBT and the South West Regional Transfusion 
Committee (SW RTC) have therefore collaborated to 
improve the efficiency of apheresis referrals. The South 
West Roadmap webpages, available on hospital.blood.
co.uk, provide an overview of the apheresis service 
providers for each relevant specialty, in the 17 Trusts in the 
region. The Roadmap* also provides direct links to referral 
forms and clinician contact details for NHSBT-delivered 
apheresis services.
Method
A web-based survey was designed and circulated in 
November 2016 to all members of the NHS Hospital 
Transfusion Teams (HTT) in the South West Regional 
Transfusion Committee. One representative from each HTT 
provided service provider information for the specialties 
within their Trust. Results were mostly obtained through 
completion of the web-based survey with the exception 
of four Trusts where results were obtained verbally or by 
email.
The results of the survey, highlighting gaps in apheresis 
services in the South West region, were presented at the 
South West Regional Transfusion Committee meeting in 
May 2017.
Results
The results of the survey showed that 41% of Trusts have 
a lack of contingency plans for circumstances when their 
primary apheresis provider is unable to deliver services. 
35% of Trusts offer no weekday out of hours or weekend 
services and 41% of Trusts have experienced difficulties 
in gaining access to therapeutic apheresis procedures over 
the last few years.
The results of this sample demonstrated that NHSBT 
provides at least one type of apheresis service for 59% 
of NHS Trusts in the South West region, either directly 
or indirectly. 35% of Trusts have a formal Service Level 
Agreement (SLA) with NHSBT, while the remainder may 
rely on ad hoc or one-off treatment requests. 
NHSBT was identified as the main service provider for 
Extracorporeal Photopheresis (59%), Leucodepletion 
(52%), Automated Red Cell Exchange (41%) and Low 
Density Lipoprotein Removal (35%), in the region. 
Low Density Lipoprotein Removal and Extracorporeal 
Photopheresis were not offered as in-house treatments in 
any Trusts. The treatments with the greatest proportion of 
in-house provision by Trusts were PEX for haematological 
conditions (41%) and Stem Cell Collection (35%).
While 82% of Trusts offered PEX for haematological 
conditions either in-house or via NHSBT, fewer Trusts 
offered PEX for other specialties, as shown in Figure 1.
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Figure 1: Proportion of Plasma Exchange Service Providers 
for Haematology, Renal, Neurology and Immunology/ 
Rheumatology Specialties.
Figure 2 displays a screenshot of a Trust-personalised 
webpage on the hospital.blood.co.uk website, detailing 
the apheresis service providers for the Royal Cornwall 
Hospitals NHS Trust. It demonstrates the variability between 
apheresis service providers in a Trust; while the in-house 
Renal Department provides PEX for Haematological and 
Renal conditions, Stem Cell Collections are conducted by 
the Haematology Department and patients are referred to 
NHSBT for Extracorporeal Photopheresis.
Figure 2: Screenshot of the Roadmap webpage for the 
Royal Cornwall Hospitals NHS Trust.
Discussion
The majority of Trusts surveyed (82%) reported that 
a Roadmap would be helpful. The results of the survey 
support the rationale for Roadmap development to clarify 
referral pathways and also highlighted gaps in apheresis 
service provision which needed to be reviewed. 
Trust-personalised webpages were developed to 
outline the apheresis service providers, in the South West 
of England for all applicable specialties. The webpages 
provide direct links to referral forms, and outline clinician 
contact details for NHSBT provided services. For Trusts 
without an SLA with NHSBT, the webpages also outline 
the in-house or tertiary service providers, with a link to 
the agreement form to be completed for one-off NHSBT 
requests.
The results from respondents, the majority of whom 
were Consultant Haematologists, demonstrate that 
Hospitals have variable service providers and access to 
apheresis services across the region; 41% of Trusts in the 
region reported difficulties in gaining access to therapeutic 
apheresis procedures.
The Roadmap report highlighted the specific gaps in 
apheresis service provision in order to facilitate discussions 
between Trusts and service providers. Trusts with SLAs 
with NHSBT Bristol TAS referred to difficulties in arranging 
in-patient clinical care with University Hospital Bristol 
(UHBristol) NHS Foundation Trust; this information has 
facilitated discussions between the Bristol NHSBT apheresis 
Unit and other UHBristol colleagues. Other Trusts referred 
to difficulties with budgets and transfers to tertiary 
providers.
The success of the Roadmap, at improving the clarity of 
the referral process and accessibility of referral forms, will 
be reviewed by analysing the NHSBT TAS User Satisfaction 
Survey Results for 2018 in the South West region. The 
results for 2018 will be compared to 2016, prior to the 
webpages development, to demonstrate the beneficial 
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Transfusion Guidelines at your Fingertips – “Blood Components” App
National, regional and local audits in England consistently 
show inappropriate use of all blood components; 15-20% 
of red cells and 20-30% of platelets/plasma1. One reason 
may be that those authorising blood components do not 
have easy access to recommended national guidelines – 
not only do they need to find them online, but then have 
to search the sometimes-lengthy documents for the key 
information they require. 
To support clinicians accessing these guidelines, the 
National Blood Transfusion Committee (NBTC) produced 
an indication codes for transfusion tool in April 2013 which 
amalgamated key national guidelines for adult patients, 
acting as a prompt for clinicians to facilitate appropriate 
use and to enable robust documentation of indications. To 
make the NBTC indication codes more accessible to clinical 
staff, the NHS Blood and Transplant (NHSBT) Patient 
Blood Management (PBM) Team developed bookmarks 
in September 2013. These are a popular resource with 
demand from hospitals at around 1,000 a month. 
In 2015 Ofcom reported that two thirds of people in the 
UK now own a smartphone2. Ownership of smartphones 
are higher among doctors (98.9%), of which 92.6% said 
a smartphone was ‘useful’ or ‘very useful’ to support their 
clinical duties. A report by Mobasheri et al (2015) found 
89.6% of doctors owned medical apps and used these as 
part of their clinical practice3. 
There is anecdotal evidence from Transfusion Practitioners 
that medical staff ask for an App to download to act as 
a prompt to facilitate appropriate transfusion. Until now 
none existed in England which could be recommended. 
 In June 2016, the NBTC indications were updated. 
An Anaesthetic Registrar in the South West region with 
support from an NHSBT PBM Consultant and an NHSBT 
PBM Practitioner then transferred the bookmark into 
an App – and the first Blood Codes App was born. The 
App was developed via an interactive process and the 
content optimised for digital format. In addition to the 
architecture build work required, the layout, content, 
colour etc were prepared, extensive testing was carried 
out, and finally the App was sent to the NBTC for sign off. 
The App maintained the identifiable colour features that 
were used in the bookmark. This was launched in October 
2016 and within the first 6 months 3,000 individuals had 
downloaded it. This clearly identified a demand for blood 
transfusion guidelines in a digital form. A limiting factor 
was that the Blood Codes App was only available on Apple 
(iOS) devices.
Figure 1: Screen shots of load screen and platelet NBTC 
indication codes from the original ‘Blood Codes’ App.
The original PBM bookmarks and Blood Codes App were 
not directly applicable to paediatric transfusion (including 
neonates and older children). However in February 
2017, following publication of the new British Society of 
Haematology (BSH) Guidelines on Transfusion for fetuses, 
neonates and older children (2016), the NHSBT PBM Team 
hosted a national conference on paediatric and neonatal 
PBM, which attracted over 200 delegates. For this event 
members of the BSH guideline writing group and NHSBT 
PBM Education Team developed neonatal and paediatric 
bookmarks with key indications for transfusion based on 
the new BSH guidelines, modelled on the format of the 
adult bookmarks. Following this event feedback from 
clinical colleagues included requests for this information to 
be made available on the current App. 
Figure 2: One of the two bookmarks developed from the 
2016 BSH Guideline.
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In March 2017, the NBTC and NHSBT secured funds to 
develop the App onto an Android platform and for the 
inclusion of new user journeys (the pathways of information 
for digital users) for both. This App was renamed “Blood 
Components” as it now included both the NBTC indication 
codes and paediatric transfusion indications from the BSH 
guidelines. Since late April 2017 this has been available to 
download for free from the Apple or Play store. 
 
Figure 3: Screen shot of the home page and 
Infants and Children platelet page from the new 
‘Blood Components’ App.
In addition to providing clinicians with easy access 
to best practice it is now possible to see how often this 
information is viewed, where and which are the most 
frequently used specialties and components. In May 2017, 
there were 1,134 unique visitors and the number of people 
who return to use the App has increased since release. 
Figure 4, shows the number of new and returning visitors. 
We expect this to change as time goes on and core users 
are established – something we will monitor over time. The 
plan is to further develop the App in the future, following 
user feedback. Additional areas that may be considered 
include transfusion for paediatric major haemorrhage and 
specific requirements.
Figure 4: New users are unique visitors. Returning are 
when a user accesses the App more than once in May 2017. 
Figure 5, shows the locations where the App is being 
downloaded – the majority are in the UK but like the 
guidelines and online bookmarks there is interest in other 
countries. 
Figure 5: Downloads by country in May 2017.
Figure 6, shows the screens which people interact with 
– this may change once users settle into what they need 
to access. This will give the PBM team insights into where 
more activity around education may exist and areas to 
target. 
Figure 6: Top 5 screens viewed in May 2017, these may 
represent people looking at the App upon download. 
After time, this will give useful insights into what users 
need to check guidelines on.
We hope this is a useful new tool to support hospitals 
implement national guidelines to improve safety and care 
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The Importance of Engaging Healthcare Students in Supporting the Work of 
Hospital Organ Donation Committees 
Introduction
The current supply of organs for transplantation fails to 
meet demand, with people needlessly dying every day for 
want of a transplant. Although it is unlikely that there will 
ever be enough organs to meet the demand, the knowledge 
that the UK has one of the lowest rates of consent to 
organ donation in Europe is an impetus to increase 
donation rates. One of the many recommendations made 
in the 2008 Organ Donation Taskforce report, supported 
by all four UK health departments, was the establishment 
of Organ Donation Committees within hospitals; such as 
the University Hospital of Morecambe Bay Trust (UHMBT) 
Organ Donation Committee. The committee meets 
quarterly, and has the authority to make and implement 
decisions on donation policy and practice ensuring full 
consultation with clinical and management staff is integral 
to the implementation process. 
Setting up the Committee
In line with the ambitions of the Task Force, the UHMBT 
Organ Donation Committee aims to: (1) influence policy 
and practice within the hospital trust in order to ensure that 
organ donation is considered in all appropriate situations, 
(2) ensure that a discussion about donation features 
in all end of life care, wherever located and wherever 
appropriate, recognising and respecting the wishes of 
individuals and (3) maximise the overall number of organs 
donated, through better support to potential donors and 
their families. 
The Committee consists of representatives from a range 
of medical specialities such as Emergency Medicine and 
Intensive Care, in addition to representatives from tissue 
services and operating theatres. The Committee is chaired 
by a lay member and is supported by the hospital trust’s 
clinical lead (MW), specialist nurse for organ donation (SR) 
and a medical ethicist (LM) from the local medical school. 
Despite the Committee consisting of a variety of 
members, the Committee identified the possible benefit 
of widening its representation to include local nursing 
and medical students. Whilst 90% of individuals report 
a positive outlook on the process of organ donation, it is 
often within healthcare settings where practitioners find 
difficulty in broaching the conversations with families and 
individuals (Ozdag 2001). This difficulty in communication 
may cause loss of an individual’s ability to consent to 
donation due to lack of information and awareness of the 
donation process. Whilst this demonstrates practitioners 
are at the centre of initiating the donation process (Ertin et 
al 2010), it highlights the sheer importance for healthcare 
professionals to be educated about organ donation, its 
process and how to break down communication barriers 
when discussing donation with individuals and their close 
relatives (NHSBT 2012). These initial conversations are 
crucial to establishing contact with NHSBT, yet it has been 
noted that nurses express concerns due to their lack of 
knowledge and understanding in regard to the concept 
of donation (Lin et al 2010); whilst medical students 
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display lack of knowledge surrounding the subject also 
(Bardell et al 2003). Furthermore, transplantation is not 
a fundamental part of the curriculum for either of these 
professions, resulting in practitioners feeling out of depth 
and uncomfortable with the scenario of possible donation 
due to a lack of experience and understanding (Anker et 
al 2009). 
In light of this, the UHMBT Organ Donation Committee 
alongside Lancaster Medical School joined forces to create 
two Student Representative posts (OA, ZB) that could feed 
into the work of the Committee to address these issues 
and raise the profile of organ donation amongst the local 
student population. The overarching role of the Student 
Representatives being to: (1) actively participate in organ 
donation committee meetings, (2) identify opportunities for 
nursing and medical students to contribute to discussions 
relating to organ donation at a local and national level and 
(3) feedback to nursing and medical students on organ 
donation policy and practice developments at a local and 
national level.
Students were required to submit an application and 
were interviewed to elucidate why they wanted to apply 
for the role, how it would relate to their future careers, 
and how they would contribute to the work of the 
Committee. Zoe Butler, a third year nursing student at The 
University of Cumbria and Oluwayemisi Alabi, a fifth year 
medical student at Lancaster University were appointed 
representatives for the Committee and led a newly formed 
sub-committee involving other students. 
Once formed, the Student Representatives organised an 
initial meeting with the sub-committee with representation 
from the UHMBT Organ Donation Committee present to 
discuss the aims for the academic year. The sub-committee 
recognised that family decline is currently the biggest 
obstacle to donation and that families are more likely to 
agree to donate their deceased relative’s organs if their 
wish to donate was known to them. With this in mind the 
student sub-committee decided that their primary goal for 
the year would be to encourage students and members of 
the local community to inform their families of their wishes 
towards donation. Against this backdrop, the first activity 
the student sub-committee decided to host was ‘Tell 
Your Family day’. This was a virtual day that was meant to 
emulate other similar virtual events for health matters, such 
as World Mental Health Day. The main ethos behind the 
day was to encourage students to start a conversation with 
their peers and loved ones about their views and wishes 
towards donation. It was recognised that this would help 
raise awareness on the importance of informing family 
of individual’s wishes towards organ donation. To help 
publicise the event, the Student Representatives set up a 
stall on Lancaster University campus, promoting the event 
to the student community. They encouraged people who 
expressed an interest, to join the organ donation register 
as a way to actively show their family their wish to be an 
organ donor. Additionally, promotional pages were made 
on Facebook and Instagram and a live twitter feed was 
started by one of the Student Representatives (ZB) on the 
day of the event. 
For the next event, the student sub-committee wanted 
to build on its aim of encouraging the local community to 
inform their families of their wish to donate and decided to 
host an Organ Donation Café. Inspiration for this event was 
taken from the very successful Death Café’s where people 
eat cake, drink tea and discuss death in a safe and friendly 
environment. The event was planned to take place during 
the organ donation week in September 2017 utilising the 
raised promotion of organ donation that occured during 
the week. Again, the spirit of the event was simply to 
encourage people to have a conversation about organ 
donation in whatever form they desire. Although leaflets 
explaining how to join the donation register was present 
for people to read if interested, like the Death Café’s 
there was no wish to set an agenda for the event. The 
sub-committee just wishes to recognise the importance 
of conversations around organ donation being the norm 
and one of the ways to removing barriers that currently 
prevent engagement with organ donation and sees this as 
one way this can be achieved. 
The final event the committee has organised is a 
community day whereby local school students were invited 
to discuss and exhibit what organ donation means to them 
through mediums such as poetry, photography, drawing, 
painting and pottery. Local medical and nursing students 
will be invited to participate in, and watch, debates relating 
to the ethical and legal aspects of organ donation. 
Conclusion 
The UHMBT Organ Donation Committee have been 
delighted with the work of the student sub-committee and 
have initiated the recruitment process for students to join 
the Committee for the next academic year. The student 
sub-committee have illustrated the importance of creating 
learning and development opportunities that tackle theory 
and concepts surrounding organ donation for healthcare 
students during their training, so that they are better 
equipped to engage in discussions and communicate the 
importance of organ donation in their practice. It is hoped 
that such improvement in communications surrounding 
the subject will create better outcomes in relation to the 
number of individuals becoming organ donors (López-
Montesinos et al 2010).
< 10 Blood and Transplant Matters – November 2017
Oluwayemisi Alabi 
5th year Medical Student  
Lancaster Medical School 
Email: oyinalabi@doctors.org.uk
Zoe Butler 
3rd year Nursing Student  
The University of Cumbria  
Email: s1400038@uni.cumbria.ac.uk 
Laura Machin  
Senior Lecturer in Medical Ethics  
Lancaster Medical School 
Email: l.machin@lancaster.ac.uk
Sarah Ralley  
Specialist Nurse for Organ Donation  
North West Team  
Email: sarah.ralley@nhsbt.nhs.uk 
Mark Wilkinson 
Consultant Respiratory and Critical Care 
Royal Lancaster Infirmary  
Email: mark.wilkinson1@mbht.nhs.uk 
References:
Anker AE, Feeley TH, Friedman E, et al. (2009). 
Teaching organ and tissue donation in medical 
and nursing education: a needs assessment. Prog 
Transplant;19:343–8.
Bardell T, Hunter DJW, Kent WDT, et al (2003). 
Do medical students have the knowledge needed to 
maximize organ donation rates? Can J Surg;46:453–7
Ertin H, Harmanci AH, Mahmutoglu FS, et al. (2010). 
Nurse-focussed ethical solutions to problems in organ 
transplantation. Nurse Ethics; 17:705–14.
Lin LM, Lin CC, Lam HD, et al. (2010) Increasing the 
participation of intensive care nurses to promote 
deceased donor organ donation. Transplant Proc ; 
42:716–18
López-Montesinos MJ, Manzanera Saura JT, Mikla M, et 
al (2010). Organ donation and transplantation training 
for future professional nurses as a health and social 
awareness policy. Transplant Proc; 42:239–42.
NHSBT (2012). Organ donation and transplantation: 
activity report 2011/12. Bristol: NHSBT.
Organ Donation Taskforce. (2008) Organs for transplants: 
a report from the Organ Donation Taskforce. London: 
Department of Health.
Ozdag N. (2001) The nurses knowledge, awareness 
and acceptance of tissue-organ donation. EDTNA ERCA 
J;27:201–6.
The National Institute for Health Research Blood and Transplant Research 
Unit in Organ Donation and Transplantation 
Introduction
The National Institute for Health Research Blood and 
Transplant Research Unit (BTRU) in Organ Donation and 
Transplantation is an equal partnership between the 
University of Cambridge, Newcastle University and NHS 
Blood and Transplant (NHSBT). The BTRU was established 
in October 2015 after a competitive application process 
and is funded by a £3.8M National Institute for Health 
Research (NIHR) grant that will run until 2020. The 
overarching strategic aim of the BTRU is to develop and 
evaluate novel approaches and technologies that increase 
the availability in the UK of suitable donor organs for 
transplantation, while improving long-term graft survival.
The management and governance of the BTRU are now 
well established, with an annual programme of regular 
face-to-face and teleconference meetings. The face-
to-face meetings (combined Management Group and 
progress update meetings) alternate between Cambridge 
and Newcastle and the two held during 2016–17 were 
each attended by over 40 delegates. The work of the 
BTRU is overseen by an Independent Scientific Advisory 
Group (Professor Giovanna Lombardi, Ms Lorna Marson, 
Professor John Cleland, Professor Simon Johnson and Mr 
Luke Devey).
The BTRU is already producing innovative work 
that has changed clinical practice in organ donation 
and transplantation. In particular, advances in renal 
normothermic organ preservation using perfusion 
machines have led to the introduction of this technology in 
two non-BTRU UK transplant units (Guy’s Hospital, London 
and Edinburgh Royal Infirmary). These advances have been 
applied to lung and liver transplantation in Cambridge and 
Newcastle.
Organisation of the BTRU
The BTRU has five main research themes and four cross-
cutting themes. A great range of work is being undertaken 
and it is only possible to give a flavour of each theme here. 
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Theme 1: Improving organ donor management and 
evaluating novel interventions, is led by Professor John Dark 
in Newcastle and Professor Chris Watson in Cambridge. This 
theme is developing normothermic perfusion techniques for 
the heart and the liver. One of the main achievements has 
been the introduction of normothermic regional perfusion 
(NRP) for donation after circulatory death (DCD). NRP uses 
cardiopulmonary bypass technology to re-establish the 
circulation of oxygenated blood through the thoracic and 
abdominal organs immediately after donor death. Liver 
transplants from DCD donors have previously had a high 
incidence of biliary complications but the pilot series of 
livers transplanted after NRP has been notable because of 
a complete absence of ischaemic cholangiopathy. 
Theme 2: Novel approaches for assessing donor organ 
quality, is led by Mr Colin Wilson in Newcastle. This theme 
is concentrating on the use of non-invasive methods for 
assessing the quality and transplantability of organs from 
marginal donors. The techniques being investigated include 
the liver maximal capacity test and an iPad-based test to 
quantify the level of hepatic and pancreatic steatosis.
The histological evaluation of pre-transplant donor 
kidney biopsies also forms a fundamental part of the 
theme. This work is being directed by Mr Gavin Pettigrew 
in Cambridge and his NIHR funded Pre-Implantation Trial 
of Histopathology In renal transplant Allografts (the PITHIA 
trial) is due to start in October 2017.
Theme 3: Resuscitating and reconditioning thoracic 
organs ex vivo, is led by Professor Andrew Fisher in 
Newcastle. Members of this theme are the national 
leaders in ex vivo lung perfusion (EVLP). The mechanisms 
of leucocyte–endothelial interactions during EVLP have 
been evaluated using a microfluidics platform. Following 
on from this, major progress has been made towards 
the identification of improved biomarkers of donor 
lung viability and future graft function. More than 40 
biomarkers of tissue integrity, microvascular integrity, 
inflammation and damage-associated molecular patterns 
(DAMPs) have been evaluated in donor lungs undergoing 
EVLP. Interleukin-1ß has been identified as a key predictive 
marker of lung viability. Work is underway to develop a 
sufficiently fast cytokine assay to allow real-time decision-
making during EVLP. This work has recently been published 
in the Journal of Heart and Lung Transplantation, which is 
the highest impact journal in the transplant field.
Theme 4: Resuscitating and reconditioning kidneys 
ex vivo is led by myself and Dr Sarah Hosgood in 
Cambridge. Normothermic machine perfusion (NMP) has 
been introduced into clinical practice in Cambridge and 
Newcastle. A Kidney Research UK funded randomised 
clinical trial of NMP in DCD kidney transplantation has 
recruited 80 patients in the first year. A series of kidneys 
declined by all UK transplant centres have been successfully 
transplanted after assessment and resuscitation by NMP. 
This work was awarded the British Journal of Surgery Prize 
in May 2017. 
In a collaboration with Professor Jordan Pober at Yale 
University, antibody-coated nanoparticles have been 
successfully targeted to the microvascular endothelium 
during NMP of discarded human kidneys. The long-term 
aim is to develop nanoparticles as a novel therapeutic 
targeting strategy for pre-transplant allograft treatment 
and immune modulation. 
Theme 5: Improving organ allocation and protecting 
long-term graft function, is led by Professor John 
Trowsdale in Cambridge. A sophisticated human leucocyte 
antigen (HLA) histocompatibility algorithm has been 
created using advanced bioinformatics and computational 
modelling techniques. This has been shown to predict HLA 
immunogenicity, based on structural and 3-D electrostatic 
charge differences between donor and recipient HLA. 
This tool has now been validated by showing that it 
accurately predicts donor-specific alloantibody production 
in a unique cohort of patients undergoing lymphocyte 
immunotherapy. Novel killer immunoglobulin receptor 
(KIR) typing is also being developed based on high-
throughput sequencing after capture.
Theme 6: Bioinformatics and biostatistics (cross-
cutting), was led by Professor Dave Collett but following 
his recent retirement leadership of this theme has been 
taken over by Rachel Johnson. This theme provides 
essential statistical support to all the other BTRU themes. 
An example of this is the complex biostatistical analysis 
required to develop the new HLA histocompatibility 
algorithm by Theme 5. Clinical trial expertise has also been 
provided to help with the design, conduct and analysis of 
the PITHIA trial (Theme 2). 
Theme 7: Biomarkers and genomics (cross-cutting), is 
led by Dr Menna Clatworthy at the Laboratory of Molecular 
Biology in Cambridge. The theme provides capacity in 
ribonucleic acid (RNA) extraction and sequencing and 
has expertise in bioinformatics. Considerable progress has 
been made using transcriptomic and proteomic analysis 
of tissue samples from Themes 1–4. For example, lung 
samples taken pre- and post EVLP (Theme 3) have been 
analysed to identify genes and pathways upregulated or 
downregulated by EVLP and those that significantly differ 
between lungs that pass or fail EVLP. 
Theme 8: Mitochondrial biology (cross-cutting), is 
led by Dr Mike Murphy in the Medical Research Council 
(MRC) Mitochondrial Biology Unit in Cambridge. In 
collaboration with Mr Kourosh Saeb-Parsy’s group a 
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mitochondrial-targeted protective agent (MitoQ) has been 
investigated using discarded human kidneys undergoing 
NMP. This approach has the potential to reduce post-
transplant ischaemia-reperfusion injury and this work 
was awarded the 2016 Royal Society of Medicine Future 
Projects Prize.
Theme 9: Novel interventions: pharmaceuticals and 
immunomodulators (cross-cutting), is led by Professor 
John Kirby in Newcastle. The main interests of this theme 
lie in the role of sphingosine one phosphate receptors 
and leucocyte–endothelial cell interactions during ex vivo 
organ perfusion. MicroRNAs are also under study as a 
target for modifying graft function. Initial results show a 
pro-fibrotic action of miRNA-21, whilst antisense to miR-
24 increases the expression of protective genes during ex 
vivo perfusion.
Patient and Public Involvement and Engagement
The BTRU is committed to patient and public 
involvement and engagement in our open society. A 
Patient and Public Research Panel (PPRP) of 24 members 
has been established and has contributed to the success of 
the BTRU in many ways. Two PPRP members have joined 
the Management Group and attended BTRU meetings. 
Their feedback has been some of the most constructive in 
improving communication between the BTRU and patients 
and the public. 
A range of BTRU events involving patients and the 
public have taken place over the last 12 months. At the 
2017 Cambridge Science Festival members of the BTRU 
delivered a public lecture on the current goals for research 
in organ donation and transplantation. The quality of the 
questions from the audience was at a higher level than 
that experienced at many national scientific meetings. 
Open days that included ‘wet lab’ demonstrations of organ 
perfusion techniques have also been held in Cambridge. 
These were well received and further sessions have been 
requested. 
One of the most successful and enjoyable interactions 
between the BTRU and patients/public was the ‘elevator 
pitch’ session at the trainees’ research day in March this 
year. Trainees delivered a brief presentation showcasing 
their research and this was followed by robust questioning 
from a panel of lay members. Their constructive 
feedback on the clarity and effectiveness of the trainees’ 
communication skills was very helpful.
Engagement with Industry
The establishment of partnerships with industry 
is critically important to the success of the BTRU. A 
number of successful relationships are already in place 
with the following companies: A1M Pharma in Sweden 
(to investigate the role of a human endogenous free 
radical scavenger in renal ischaemia-reperfusion injury); 
Organ Assist, Netherlands (to further develop liver and 
kidney perfusion systems); Maquet, USA (to develop the 
Cardiohelp Machine for NRP research); Aedstem Ltd, UK 
(to develop a photographic point-of-care steatosis assay); 
MyCartis, Belgium (for the development of an ultra-rapid 
detection assay for cytokines); Biovitrum AB, Sweden 
(testing an IL-1 receptor antagonist); Faraday, USA (to 
investigate a novel sulphide-based compound in ischaemia-
reperfusion injury); GlaxoSmithKline (to investigate the 
role of IL-18 blockade in renal transplantation). 
Major Grant Awards Received as a Consequence of 
NIHR BTRU Funding
The BTRU has attracted additional external funding 
amounting to nearly £2M. Notable amongst these awards 
are the Natural Killer cells in disease grant awarded to 
Professor John Trowsdale, Professor of Immunology, 
University of Cambridge (£1.48M) and the NIHR research 
for patient benefit grant awarded to Mr Gavin Pettigrew, 
Reader in Clinical and Experimental Transplantation, 
University of Cambridge, for the PITHIA trial.
Website
The BTRU website (http://odt.btru.nihr.ac.uk/) was 
created by Rachel Brown, Project Manager, who has been 
widely praised for her meticulous attention to detail. One 
of the principal aims of the website is to showcase the 
BTRU to healthcare professionals and wider society as 
an open and collaborative venture. The website is a key 
achievement in the BTRU’s pursuit of positive branding.
Earlier this year four BTRU themes produced short 
videos to explain their work to a lay audience. The patient 
and public panel voted on the videos’ understandability, 
effectiveness in delivering learning, ability to hold their 
interest, and audiovisual quality and a prize was awarded. 
These videos have been posted on the website. We look 
forward to the continuing evolution of the website, with 
the aim of developing greater interactivity with patients 
and the public. 
Summary
The strategic partnership between the University 
of Cambridge, Newcastle University and NHSBT has 
demonstrated that the whole can be greater than the sum 
of the parts. In parallel with delivering ground-breaking 
translational research, the BTRU has a passion to increase 
patient and public involvement in its work. Good progress 
has been made so far but in the future the aim will be 
to involve patients and the public in identifying the best 
research questions and in planning research projects.
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The BTRU trainees’ day in March 2017 brought together 
senior scientists and clinicians, patients and the public in 
a highly successful and interactive format. Presentations 
of the early work suggested that the BTRU has been 
successful in recruiting, placing and equipping scientific 
and clinical PhD students.
Alongside the strategic priority of ensuring effective 
bidirectional translation between basic biomedical and 
clinical research we have developed strong links with 
industry and feel that this will be important to the future 
success of the BTRU.
In conclusion, the NIHR BTRU in Organ Donation and 
Transplantation is now in its second year and is being 




Professor of Transplant Surgery 
University of Cambridge 
Director of the NIHR BTRU in Organ Donation 
and Transplantation
Donation Memorials
Many from the donation and transplant community 
consider donation as the greatest gift one person can give 
another in peacetime. Just as we remember those who 
gave so much to save others in times of war, so we should 
remember those who gave so much to save others in times 
of peace. 
Recommendation 12 of the 2008 Organ Donation 
Taskforce report called for, “Appropriate ways should be 
identified of personally and publicly recognising individual 
organ donors, where desired. These approaches may 
include national memorials, local initiatives and personal 
follow-up to donor families.”
In the UK, many hospital Organ Donation Committees 
have answered this challenge, and created local memorials 
of remembrance and thanks for deceased organ and 
tissue donors. One day we hope that every UK hospital 
will have a donation memorial. We’d like in this article to 
illustrate just a few of the many; highlighting both national 
and local initiatives. Our apologies that space does not 
allow us to feature all of them, but if you would like to 
see more visit Dale’s personal website www.clodlog.com/
donationmemorials where he displays as many as he has 
photos of.
The Gift of Life Memorial – designed by Julia Hennessey-
Priest for the Donor Family Network. National Memorial 
Arboretum, Staffordshire
The Gift of Life Stone, Alexandra Gardens, Cardiff. 
Donated by the Kidney Wales Foundation.
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Taigh House, Scottish National Donation Memorial 
in the Royal Botanical Gardens, Edinburgh.
‘The Gift’ – Worthing and St Richards Hospitals, West 
Sussex Hospitals NHS Foundation Trust.
Organ Donation Memorial Garden, Noble’s Hospital, 
Isle of Man
Donor Celebration Sculpture, Russells Hall Hospital. 
The Dudley Group NHS Foundation Trust.
 
Dale Gardiner 
Deputy National Clinical Lead for Organ 
Donation 
Nottingham University Hospitals/NHSBT 
Email: dale.gardiner@nhsbt.nhs.uk
Sarah Beale 
Team Manager – South Wales 
Organ Donation & Transplant 
NHSBT, South Wales 
Email: sarah.beale@nhsbt.nhs.uk
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Our Ladder of Opportunity
In November 2016, NHS Blood and Transplant launched 
its Apprenticeship Scheme and so far, we are pleased to 
announce that 120 employees have started or registered 
their interest to start an apprenticeship programme. From 
the outset, our approach to Apprenticeships has been that 
they will form a fundamental part of our People Strategy 
at NHSBT; they will provide further opportunities for us to 
demonstrate that we will:
• Attract the Best People – by offering apprentice 
opportunities for vacancies, particularly for Band 2 posts 
initially.
• Develop and Grow Our Talent – by offering a wide 
range of apprenticeship programmes that can be studied, 
across all Directorates throughout England. 
• Retain Our People and Skills – by offering 
apprenticeship opportunities to existing employees, 
particularly those who may not have had the chance 
previously to gain recognised qualifications. 
• Lead with Passion – by engaging with Line Managers 
throughout the entire apprenticeship journey.
• Create the Right Environment – by working with 
Senior Leaders and Business Partners to ensure that 
our apprenticeship offering meets the needs of our 
organisation now and can be developed and sustained 
to meet future requirements.
Across all industries, including the wider NHS, there is 
a growing view that apprenticeships are a great step on 
the ‘ladder of opportunity’. They are a chance for people 
to learn new key skills whilst gaining real experience in 
the workplace, improving long term career prospects, and 
obtain an accredited qualification upon completion, whilst 
not having to get into debt as the training/qualification 
aspect is funded. 
Apprenticeships are not just for young people; they 
are open to colleagues of all ages. NHSBT are offering 
programmes at Level 2 and 3; these are the equivalent to 
completing a GCSE (Level 2) or A Level (Level 3) qualification. 
There are currently eight programmes available to complete 
including Business Administration, Customer Services, 
Healthcare Support Service, Logistics Operations and Team 
Leading. Each of our current apprenticeship programmes 
lasts for minimum duration of 12 months and 1 day. Our 
People First page has all the details at http://peoplefirst.
nhsbt.nhs.uk/nhsbt-apprenticeships.htm. 
Apprenticeship opportunities can be accessed by all our 
eligible employees, across all directorates and functions 
within NHSBT. Our scheme has two strands of access; for 
new starters recruited as an apprentice initially at entry 
level and for our existing employees who want to enhance 
their skills and experience in their current job roles. We 
offer four intakes per year for existing employees. If a 
manager is interested in employing an apprentice as a new 
starter to fill a vacancy at Band 2, this can be done at any 
time. You do not need to wait for an intake because the 
normal recruitment process applies. 
From 1 April 2017, a new apprenticeship levy has come 
into effect that requires all companies with a payroll 
totalling £3 million or more to invest 0.5% into the 
government’s apprenticeship scheme. Our activity that 
ties in to this duty includes broadening our scheme to 
reflect the diverse range of job roles within NHSBT. We are 
also planning access to Intermediate (Level 2; equivalent 
to GCSE’s), Advance (Level 3; equivalent to A Levels), 
Higher (Level 4; equivalent to a HNC) and Degree (Levels 
5 to 7; equivalent to a Foundation Degree to Masters) 
Apprenticeships in the future. From 2018, we will be 
offering over 40 different apprenticeship programmes. 
This will include apprenticeship pathways in Science, 
Management and Healthcare Support to name a few. 
This will be a great opportunity to offer a broad range 
of apprenticeships, which will also be an alternative to 
university (Degree Levels). 
Our apprentices have provided some feedback on their 
experiences and have provided an overview of some of the 
benefits of completing an apprenticeship, as follows:
“I have always been a hands-on learner. I find I am 
much more interested in working and getting experience 
than just attending education, so the opportunity to 
combine the two was perfect for me. I enjoy the working 
environment and find I gain better knowledge when 
experiencing the work.” Chloe Fitzpatrick-Creamer, 
Clinical Business Administration Apprentice (Clinical 
Directorate)
“I was searching for jobs after taking a short break 
from completing my A Levels, and came across an 
apprenticeship advertised with NHSBT. It was advertised as 
a two-year apprenticeship (Customer Service followed by 
Business Administration) with a permanent job at the end 
of the two years. I decided to apply as I would be able to 
gain two further qualifications whilst gaining experience 
in the workplace.” Livvy Upton, Senior Organisational 
Development Administrator (Workforce Directorate)
“I believe the apprenticeship can only be positive for my 
future. New skills are always a plus and by putting them 
into action during this programme I can gain the experience 
necessary to advance in my career.” Tim Keenan, Donor 
Carer (Blood Donation Directorate)
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“It doesn’t matter what age you are, if you lack experience 
or what qualifications you have, an apprenticeship is the 
perfect option if you feel college isn’t the route for you 
or you fancy a change of career.” Tyisha Beighton, 
Recruitment Business Administration Apprentice 
(Workforce Directorate)
We have received a high level of interest in our 
programmes, to the point where we have reached 
capacity for existing employee starts this year. We are 
however still able to support any requests for new starters; 
submit a recruitment request in your normal way. Our 
new programme offering, including our approach for the 
next 3 years, will be launched towards the end of 2017. 
Please do keep a look out on what’s on offer and submit 
an expression of interest through People First if you are 
interested to start a programme. Our cohorts for our 
existing employees will be on a first come, first served 
basis, therefore get your application submitted as soon 
as possible. New starters can be recruited at any point; 
therefore, there is no need to wait.
For further information on our scheme or future plans, 
please visit our Apprenticeship page on People First (link 
above), or alternatively, you can contact Laura Unitt, 
NHSBT Apprenticeship Manager (contact details below). 
 
Laura Unitt 
NHSBT Apprenticeship Manager 
NHSBT, Birmingham 
Email: laura.unitt@nhsbt.nhs.uk 
A New Leeds/Sheffield Centre 
The existing blood centres in Leeds and Sheffield have 
been in existence for over 40 years and pre-date the 
creation of NHS Blood and Transplant (NHSBT). They are 
only 35 miles apart and occupy a footprint of around 
15,500m2.
Due to successive consolidations in manufacturing, 
testing and warehousing over recent years this is now 
approximately double the space that NHSBT currently 
requires. The impending move of manufacturing from 
Sheffield to Manchester in 2017 further exacerbates the 
situation.
Following a detailed review of the options, a single new 
centre located between Leeds and Sheffield has been 
identified as the best way forward for NHSBT and offers 
the optimal combination of financial and non-financial 
benefits. The new centre would accommodate all services 
from the existing centres, with the exception of blood 
collection team bases. These would remain at new sites 
close to the current locations, and warehousing, which is 
being relocated as part of a separate project.
A preferred site for the new centre, close to Junction 
37 on the M1 has been identified and it is proposed that 
NHSBT enters a minimum 25 year lease and construct 
a purpose-built, flexible, efficient and modern facility, 
with some scope for future expansion, by June 2020. In 
addition to the new centre we will also retain a team base 
in both Leeds and Sheffield. The existing centres would be 
transferred to the government’s Homes and Communities 
Agency for disposal.
The capital cost to fit out the new centre will be 
£14.5m, plus £0.6m for the two team bases, and with 
£2.3m assumed as the proceeds from the sale of the Leeds 
and Sheffield sites. The project will generate recurring 
net revenue savings of £1.1m pa (i.e. to blood prices). 
The financial case is, however, driven by the avoided 
cost of maintenance and refurbishment of the existing 
sites (£16.1m over 10 years). Taking this into account the 
project generates a payback of 3.6 years (from the point of 
operational commissioning).
There has been extensive communication with 
employees and customers with their responses taken into 
account with regard to location, design and internal fit out. 
As with any project that involves relocation of stock holding 
units and laboratories we have been especially sensitive to 
the concerns of customers, especially those to the north 
and east of Leeds who will see potentially longer delivery 
times, albeit well within our Service Level Agreement. In 
recognition of this development, the proposal was delayed 
by three months to enable a programme of engagement 
by the Customer Services team with hospitals to outline 
the existing “problem” and engage them in identifying the 
solution.
A benefit of the location for the new centre is that it will 
establish a new ‘hub’ for services to hospitals in Red Cell 
Immunohaematology (RCI) as well as opening up greater 
collaboration in Histocompatibility and Immunogenetics 
(H&I) and potential expansion of Cellular and Molecular 
Therapies (CMT). In this regard the project includes the 
construction of new clean rooms to meet increasing 
demand for new cellular therapies in a cost-effective 
manner that meets modern manufacturing standards. 
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A new centre between the two existing centres 
has a lower impact on employees overall but there 
are, of course, significant impacts at an individual 
level, often positive but in some cases less so. We 
have therefore engaged extensively with employees 
from the start including, centre wide presentations, 
workshops, visits to the shortlisted sites, monthly 
newsletters and involvement in the design of the 
working spaces. We will continue to work closely 
with all stakeholders as the project progresses.
The business case for the proposals was approved by 
the NHSBT Board in May 2017 and we gained Department 
of Health approval in September 2017. Following that, 
we would plan to acquire the site by the Autumn and 
complete the build of the main structure by Autumn 2018. 
We would then expect to complete the fit out of the new 
centre in December 2019 allowing phased occupation to 
follow, with completion planned for June 2020.
 
Chris Sims 
Assistant Director of Finance 
NHSBT, Leeds 
Email: chris.sims@nhsbt.nhs.uk
Donating Aoife’s Organs was an Easy Decision to Make
Aoife Marie O’Sullivan, born on 19 May 2011, from 
Leigh-on-Sea, Essex was waiting for a heart transplant 
when she died aged 4½ and became an organ donor 
herself.
She passed away on 2 March 2016 after suffering from 
overwhelming brain damage as a result of her heart failing 
and both of her kidneys were donated to a young man. 
Aoife had been diagnosed with restrictive 
cardiomyopathy in December 2015 – a condition that 
meant her heart muscle was rigid and could not pump 
properly – and a heart transplant was her only chance of 
her life being extended.
She died in Great Ormond Street Hospital, shortly after 
emergency surgery to fit a Berlin Heart following a rapid 
deterioration in her condition. 
Aoife’s parents, Michelle and Neil, said “All Aoife’s 
mechanical support was removed allowing her to pass on 
peacefully. We decided to allow her organs to be donated 
in the hope that in her passing she can also give the gift 
of life to others. We both take comfort in knowing that in 
death our little Angel might have helped to save another 
life. We can’t stress how important it is to register yourself 
and your families to be an organ donor. Life is special 
and the greatest gift you can give is to register for organ 
donation.”
Michelle and Neil also have a 19 month old daughter 
called Emilie.
Aoife had just started school when her illness became 
more apparent.
Michelle said: “Aoife was a typical lovely four year old. 
She had just started in reception class at school, and was 
making friends and enjoying herself.”
Aoife had a persistent cough in the 12 months before 
diagnosis and the GP put it down to asthma. Her family 
later found it was a sign of restrictive cardiomyopathy, 
which is a rare condition.
By late November, she had been sent home from school 
a couple of times for coughing and was initially diagnosed 
with pneumonia after an emergency attendance at 
Southend Hospital’s Accident and Emergency (A&E) 
department. Tests at Southend Hospital and later the Royal 
Brompton Hospital found she had an enlarged heart and 
the condition was diagnosed. She was taken straight to 
intensive care at the Royal Brompton. In December she was 
admitted to Great Ormond Street, but was too ill to return 
home for Christmas. In January Aoife was responding well 
to medication and was allowed home. After approximately 
two weeks, she became gravely ill and was readmitted 
to Great Ormond Street. She died on 29 February and 
became a donor on 2 March. It was not possible to donate 
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”Bringing Key Guidelines to your Fingertips” 
Hospital doctors, the National Blood Transfusion 
Committee and the NHS Blood and Transplant Patient 
Blood Management Team have developed an App to allow 
you to access key guidelines when you need them.
The app is based on the National Blood Transfusion 
Committee (NBTC) Indication Codes for Transfusion in 
Adults (2016) and the British Society of Haematology 
(BSH) Guideline on transfusion for fetuses, neonates and 
older children (2016).
The App is free to download and provides indications for 
appropriate use of blood components at your fingertips.
You can download the app for Android and iOS (Apple). 
Search “Blood Components” in your App or Play Store.
Please share this App with your colleagues and 
encourage them to download and use it.
any organs other than her kidneys because of the cocktail 
of medications she had been on while on life support.
Michelle said: “Donating Aoife’s organs was an easy 
decision to make. It was the right thing to do. Neil and I 
feel proud and take comfort from that fact that Aoife has 
given somebody an extension of their life and more time 
with their loved ones. I would say to people ‘put yourself 
in the shoes of someone waiting for a transplant. If you 
are willing to accept an organ donation, it is only right that 
you should be willing to donate the special gift of life to 
another family. Please sign the organ donation register for 
yourselves and your family’. 
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CPD Questions
1. A Web Based Road Map:
a) As NHSBT provides all Therapeutic Apheresis 
Service (TAS) to the NHS in the South West 
of England no Road Map is required.
b) As each NHS Trust provides a full and 
comprehensive TAS in the South West of 
England, no Road Map is required.
c) Access to TAS is unclear for some NHS Trusts, 
in the South West of England so a Road Map 
may be useful.
d) There are no TAS to the NHS in the South West 
of England.
2. A Web Based Road Map:
a) There are no time-to-treatment critical factors for 
any condition treated by Therapeutic Apheresis.
b) Only TTP has a recommended minimum time-to-
treatment, to ensure a good outcome.
c) All conditions treated by Therapeutic Apheresis 
have a minimum time-to-treatment to ensure 
a good outcome.
d) TTP and other Therapeutic microangiopathies 
have recommended minimum time-to-treatment, 
to ensure a good outcome.
3. A Web Based Road Map, detailing the 
Apheresis provided for each Trust:
a) Was available in the North West of England 
and North Wales from 2013.
b) Is available for the whole of the UK.
c) Is available for the whole of England and Wales.
d) Is available for the whole of England.
4. The South West Regional Transfusion 
Committee Found:
a) All trusts have a contingency plan for 
circumstances when their primary apheresis 
provider is unable to deliver services.
b) 35% of Trusts offer no weekday out-of-hours 
or weekend services.
c) 25% of Trusts had experienced difficulties in 
gaining access to TAS procedures.
d) Over half of Trusts have a formal Service Level 
Agreement with NHSBT for TAS.
5. NHSBT provided:
a) Over half of all Extracorporeal Photopheresis.
b) Less than half of all TAS for Leucodepletion.
c) Over half of all Automated Red Cell Exchange.
d) Less than a third of all TAS for Low-density 
Lipoprotein removal for Trusts in the South West.
6. Blood Components App: All audits in England 
consistently show.
a) Appropriate use of all blood components.
b) Inappropriate use of less than 5% of Red Cells.
c) Inappropriate use of less than 15-20% of 
Red Cells.
d) Inappropriate use of between 20-30% of 
Red Cells.
7. In 2015 Ofcom reported that:
a) Over 90% of people in the UK now own 
a smart phone.
b) Less than 50% of people in the UK now own 
a smart phone. 
c) One third of people in the UK now own 
a smart phone
d) Two thirds of people in the UK now own 
a smart phone. 
8. The Blood Component App:
a) Is only applicable to adults.
b) Is only applicable to haematology patients.
c) Includes paediatric transfusion indication.
d) Does not include paediatric transfusion 
indication.
9. The Blood Component App:
a) Is only available in beta mode.
b) Is available to download for free.
c) Is available to download from Apple Store Only.
d) Is available to download from Play Store Only.
< 20 Blood and Transplant Matters – November 2017
10. The National Institute for Health Research 
Blood and Transplant Research Unit in Organ 
Donation of Transplantation is an equal 
partnership between:
a) University of Cambridge and 
Newcastle University.
b) University of Cambridge and NHSBT.
c) University of Cambridge and 
Newcastle University and NHSBT.
d) Newcastle University and NHSBT.





Main research themes and four cross-cutting themes.
12. The cross-cutting themes include
a) A bioinformatics and biostatistics theme.
b) Resuscitation and reconditioning kidney ex vivo 
theme.
c) A resuscitation and reconditioning thoracic 
organs ex vivo theme.
d) A theme developing Homothermic perfusion 
techniques for the heart and liver.
13. The Biomarkers and Genomic Theme uses 
Samples from: 
a) Theme one only.
b) Themes one and two.
c) Themes one, two and three.
d) Themes one, two, three and four.
14. The BTRU:
a) Does not engage with industry.
b) Has a Patient and Public Research Panel.
c) Has no lay public involvement.
d) Has no patient involvement.
15. A New Leeds/Sheffield Centre:
a) The present Leeds and Sheffield Centres occupy 
a foot print of around 15,500m2.
b) The present Leeds and Sheffield Centres are less 
than 20 years old.
c) The present Leeds and Sheffield Centres would 
need less than £10 million over the next 10 years 
on maintenance and refurbishment.
d) The proposed new site is North of Leeds.
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Clinical Case Studies
Question 1
Leukaemia relapse is still one of the main causes for 
mortality and significant morbidity following allogeneic 
stem cell transplantation. Donor lymphocytes can be 
infused to control early Leukaemia relapse and maintain 
remission. Sometimes repeated carefully titrated doses 
of lymphocytes need to be infused over many weeks or 
months. Donor Lymphocytes Infusion (DLI) can trigger 
GVHD. Moreover not all Leukaemia responds well to DLI.
Which of the following is most likely to respond to DLI?
1. Acute Myeloid Leukaemia.
2. Acute Lymphoblastic Leukaemia.
3. Chronic Myeloid Leukaemia
4. Chronic Lymphoid Leukaemia.
5. Multiple Myeloma.
Question 2
Which of the following are true regarding peripheral blood 
and marrow donation from unrelated donors?
1. 60% of donors are males.
2. Epidural or spinal anaesthesia can be used for 
marrow harvest.
3. Most donors (more than 75%) achieve required 
yield with a single apheresis procedure.
4. The risk of blood transfusion following a marrow 
harvest is 0.5%.
5. More than 25% of Peripheral Blood Stem Cell 
(PBSC) donors drop their platelet count following 
apheresis to less that 100 x 109/L.
6. All blood counts return to normal within one 
month.
7. 80% of donors experience bone pains regardless 
of method of donation, but this is usually mild or 
moderate.
8. Fatigue, insomnia, constitutional symptoms are 
reported with equal frequency in both types of 
donation.
9. Women and older donors are most likely to 
become symptomatic during or following 
donation.
10. Women are five times more likely to require a 
central line for PBSC collection.
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Answers to Clinical Case Studies
Question 1
Answer 1 = C
Chronic Myelogenous Leukaemia (CML) is most likely 
to respond to Donor Lymphocytes Infusion (DLI). Acute 
Lymphoblastic Leukaemia (ALL) is least likely to respond 
to DLI. Multiple Melanoma (MM) and Acute Myloid 
Leukaemia (AML) may respond to DLI.
The response to DLI (otherwise known as graft versus 
Leukaemia effect) is very prominent in CML, probably 
because of Leukaemia cells immunogenicity and relatively 
slow growth of the tumour.
ALL is not very immunogenic and it grows very quickly 
rendering DLI ineffective.
Reference: Kolb et al (2004) Blood, 103:767-776 and ASH 
SAP 2016.
Question 2
Answer 2 = All are true
All these statements are true and they are the findings 
of an americal prospective survey for donors from NMDP 
(National Marrow Donor Programme).
References:
Pulsipher et al (2014) Blood 123(23), 3655-63
Pulsipher et al (2013) 
CPD Blood and 
Transplant Matters
Answers Issue 52
1. C 2. D 3. A 4. B 5. A
6. C 7. D 8. C 9. B 10. C
11. D 12. A 13. D 14. B 15. A
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NotesDiary Dates
17 January 
Post ASH significant Highlights - London
Location: Cavendish Conference Centre, London
For more information, contact: 
www.b-s-h.org.uk
18 January
Post ASH significant Highlights - Manchester
Location: Manchester Conference Centre, Manchester
For more information, contact:
www.b-s-h.org.uk
24 January 
Post ASH significant Highlights - Bristol
Location: Doubletree by Hilton Bristol City Centre




Location: Post Graduate Centre, Birmingham
For more information contact:
www.b-s-h.org.uk
7 – 9 March
London Haematopathology Course
Location: Bart’s and the London School of Medicine 
and Dentistry Pathology and Pharmacy Building - The 
Royal London Hospital, Whitechapel
For more information contact:
www.b-s-h.org.uk
9 – 11 March
4TH International Conference on Hematologic 
Malignancy at older age: Biological and Therapy
Location: Centre Mandeliew, France
For more information, contact:
www.esh.org
3-4 April
Venesection and Haemochromatosis – Sharing 
Best Practice
Location: Paddington, London
For more information contact:
www.b-s-h.org.uk
16 -18 April
58th Annual Scientific Meeting of the British 
Society for Haematology
Location: ACC Liverpool
For more information contact:
www.b-s-h.org.uk
18 – 20 April
ESH – GR – EX 2ND INTERNATIONAL SYMPOSIUM 
ON RED BLOOD CELLS – GENESIS AND 
PATHOPHYSIOLOGY
Location: Marriott Rive Gauche Hotel, Paris
For more information contact:
www.esh.org
14 June
World Blood Donor Day
www.awarenessdays.com
13 – 17  September
37th World Congress ISH
Location: Vancouver Convention Centre, Canada
For more information contact:
www.ishworld.org
29 September – 4 October
19th Meeting of European Association for 
Haematopatholgy
Location: Edinburgh International Conference Centre
For more information contact:
www.b-s-h.org.uk
3 – 5 October 
BBTS Annual Conference
Location: Brighton
For more information, contact:
www.b-s-h.org.uk
13 – 16 October
AABB Annual Meeting
Location: Boston, MA-
For more information contact:
www.aabb.org
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